Medtronic plc (MDT)
| Market Cap | 107.03B |
| Revenue (ttm) | 33.20B |
| Net Income (ttm) | 4.26B |
| Shares Out | 1.28B |
| EPS (ttm) | 3.27 |
| PE Ratio | 25.52 |
| Forward PE | 14.49 |
| Dividend | $2.80 (3.36%) |
| Ex-Dividend Date | Mar 28, 2025 |
| Volume | 7,168,202 |
| Open | 84.13 |
| Previous Close | 84.85 |
| Day's Range | 83.24 - 84.27 |
| 52-Week Range | 75.96 - 96.25 |
| Beta | 0.83 |
| Analysts | Hold |
| Price Target | 94.71 (+13.63%) |
| Earnings Date | May 22, 2025 |
About MDT
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accesso... [Read more]
Financial Performance
In 2024, Medtronic's revenue was $32.36 billion, an increase of 3.64% compared to the previous year's $31.23 billion. Earnings were $3.68 billion, a decrease of -2.18%.
Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for MDT stock is "Hold." The 12-month stock price forecast is $94.71, which is an increase of 13.63% from the latest price.
News
Smart Pills Market Industry Trend Analysis, and Forecast 2025-2034, with Profiles of ANX Robotica, Bodycap, CapsoVision, Check-Cap, etectRx, Intromedic, Medtronic, Otsuka, Olympus and RF
Key growth drivers include the rise of gastrointestinal disorders and demand for non-invasive diagnostics. Smart pills, equipped with sensors and AI, facilitate real-time monitoring and personalized m...
Best Dividend Aristocrats For May 2025
Despite a strong start, the Dividend Aristocrats are underperforming the S&P 500 in April, with NOBL down 4.88% and SPY down 1.53%. The best-performing Dividend Aristocrats YTD include Consolidated Ed...
Medtronic Affera™ pulsed field ablation technologies continue to demonstrate promising evidence for atrial fibrillation patients
One-year clinical trial data for the next-generation, investigational, Sphere-360™ single-shot PFA catheter show impressive safety, performance, and efficiency results for paroxysmal Afib Dual-energy ...
Medtronic Expand URO U.S. clinical trial meets safety and effectiveness primary endpoints for Hugo™ robotic-assisted surgery system
Largest multi-center prospective Investigational Device Exemption (IDE) study for multi-port robotic-assisted urologic surgery in the U.S. presented as a late-breaker at the American Urologic Associat...
Medtronic receives FDA approval for smallest-diameter, lumenless defibrillation lead, the OmniaSecure™ lead and announces investigational clinical study results
Adding to the Medtronic portfolio of catheter-based lead solutions, the novel OmniaSecure defibrillation lead allows for precise delivery and placement in the right ventricle Heart Rhythm 2025: Late-b...
Medtronic advances Abbott CGM partnership with FDA submission of interoperable insulin pump
GALWAY, Ireland , April 24, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced it has submitted 510(k) applications to the U.S. Food and Drug Adm...
Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting
FDA recently granted Breakthrough Device Designation to AVIM therapy for use in patients with uncontrolled hypertension at increased cardiovascular risk HRS Satellite Symposium will feature leading ex...
Medtronic: Time To Buy This Dividend Aristocrat Bargain
In recent months, Medtronic has soundly outperformed the S&P 500 index. The company's recent regulatory approvals should bode well for non-GAAP EPS growth in the coming years. Medtronic's interest cov...
Medtronic: One Of The Best Times To Buy
Medtronic offers a compelling long-term investment opportunity with solid revenue and earnings growth, driven by innovation in the cardiovascular, neuromodulation, and diabetes care segments. Medtroni...
New Simplera Sync™ sensor for the MiniMed™ 780G System now FDA approved
Latest approval expands Medtronic CGM portfolio in the U.S. GALWAY, Ireland , April 18, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the U....
The Best Large-Cap Stocks to Buy
Large-cap stocks are key additions to any well-rounded portfolio, but how do you find the best ones? We take a closer look here.
Best Dividend Aristocrats For April 2025
Dividend Aristocrats are outperforming the S&P 500 in 2025, demonstrating resilience, with NOBL up 1.78% YTD versus SPY's 4.9% decline. Top performers include Consolidated Edison (+22.98%), Brown & Br...
Medtronic Evolut™ TAVR system shows durable clinical outcomes and outstanding valve performance at five years in low-risk aortic stenosis patients
GALWAY, Ireland and CHICAGO , March 30, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the Evol...
Medtronic: Strength In Cardiac Ablation Solutions, Upgrade To Buy
Upgraded Medtronic to a ‘Buy' rating with a fair value of $105 per share, driven by strong growth in Cardiac Ablation Solutions and TAVR markets. Medtronic reported 4.1% organic revenue growth and 6.2...
FDA classifies recall of Medtronic embolization devices as 'most serious'
The U.S. Food and Drug Administration on Tuesday classified the recall of Medtronic's embolization device as "most serious", following reports of the deaths of four patients.
The Big 3: KO, MDT, LHX
Stability is Kenny Polcari's theme when it comes to today's Big 3. He explains why Cola-Cola (KO), Medtronic (MDT) and L3Harris (LHX) are undervalued names with quality.
CGS Transforms Workplace Training with Cicero, a New AI-Driven, Customizable Roleplay Platform
NEW YORK, March 10, 2025 (GLOBE NEWSWIRE) -- CGS Immersive™, the leader in enterprise learning that is modernizing training and development with AI and XR technologies, today introduced Cicero™, a hyp...
SMART Trial two-year data continues to demonstrate superior valve performance for Evolut TAVR™ system in small annulus patients
CRT 2025 Late Breaking Science features largest head-to-head randomized control TAVR trial to primarily enroll women using the two most widely used global TAVR devices GALWAY, Ireland and WASHINGTON ,...
Medtronic announces cash dividend for fourth quarter of fiscal year 2025
GALWAY, Ireland , March 6, 2025 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE: MDT) on Thursday, March 6, 2025, approved the company's cash dividend for the fourth quarter of fiscal ye...
Medtronic explores options to optimize manufacturing operations amid Trump's tariff threats
Medical device maker Medtronic is looking at options to modify its global manufacturing footprint as part of efforts to mitigate any impact of U.S. President Donald Trump's tariff plans, a company exe...
US FDA approves Medtronic's medical device for Parkinson's disease
The U.S. Food and Drug Administration has approved Medtronic's deep brain stimulation system for use in patients with Parkinson's disease, the medical device maker said on Monday.
Medtronic earns U.S. FDA approval for the world's first Adaptive deep brain stimulation system for people with Parkinson's
New closed-loop system self-adjusts DBS therapy to individual brain activity in real time; the largest commercial launch of brain-computer interface technology ever GALWAY, Ireland , Feb. 24, 2025 /...
Medtronic plc (MDT) Q3 2025 Earnings Call Transcript
Medtronic plc (NYSE:MDT) Q3 2025 Earnings Conference Call February 18, 2025 8:00 AM ET Company Participants Ryan Weispfenning - Vice President and Head of Investor Relations Geoff Martha - Chairman a...
Medtronic Q3 Earnings: Cardiovascular And Neuroscience Drive Growth, Surgical Revenue Dips, Reaffirms Annual Forecast
Tuesday, Medtronic Plc MDT reported third-quarter 2025 sales of $8.29 billion, missing the consensus of $8.32 billion.